Mesenteric and Splenic Contributions to Portal Venous CT Perfusion in Hepatic Diffuse Disease

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 Jan 1

PMID 25550855

Citations 1

Authors

Hongzan Sun

Zaiming Lu

Hongyuan Liang

Jun Xin

Yuying Gao

Qiyong Guo

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the changes and contributions of superior mesenteric venous perfusion (SMVP) and splenic venous perfusion (SpVP) to portal venous CT perfusion in canine model of hepatic diffuse disease.

Materials And Methods: By selective catheterization in superior mesenteric and splenic arteries respectively after CT perfusion scanning, SMVP and SpVP became available. Sixteen dogs were adopted and induced by carbon tetrachloride after data under normal conditions were collected. After 3, 6, 9 and 12 months from carbon tetrachloride intervention, liver biopsies by puncture or operation were performed after CT perfusion scanning. SMVP and SpVP under different pathologic conditions were compared and analyzed.

Results: Three stages of hepatic diffuse lesions were defined according to pathologic changes, namely hepatitis, hepatic fibrosis, and cirrhosis. The number of dogs which survived from each stage was: 16 from normal, 12 from hepatitis, 10 from hepatic fibrosis and 4 from cirrhosis. During this progressive period, SpVP ml/(min·100 ml) declined slightly, but there were no significant differences between different stages (P > 0.05). SMVP ml/(min·100 ml) in stage of normal (64.1 ± 8.1) and hepatic fibrosis (44.4 ± 4.5), normal and cirrhosis (42.6 ± 5.4), hepatitis (61.3 ± 6.4) and hepatic fibrosis, hepatitis and cirrhosis was significantly different, but there was no significant difference of SMVP between normal and hepatitis (P = 0.326) or hepatic fibrosis and cirrhosis (P = 0.668).

Conclusions: With our evidence of interventional CT perfusion, it is mesenteric, not splenic, perfusion that might coincide with hepatic portal venous perfusion during the progressive period of hepatic diffuse disease.

Citing Articles

Mean standardized uptake value (SUVmean) and global hepatic glycolysis as potential imaging markers reflecting hepatic functional capacity: evidence from 18F-FDG PET/CT.

Yue X, Wang J, Ye F, Xiao D Hippokratia. 2019; 22(4):122-126.

PMID: 31695300 PMC: 6825420.

References

Kim M, Baik S, Lee S . Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol. 2011; 16(4):347-52. PMC: 3304610. DOI: 10.3350/kjhep.2010.16.4.347. View

Jang J, Kang K, Kim Y, Kang Y, Lee I . Reevaluation of experimental model of hepatic fibrosis induced by hepatotoxic drugs: an easy, applicable, and reproducible model. Transplant Proc. 2008; 40(8):2700-3. DOI: 10.1016/j.transproceed.2008.07.040. View

Lin D, Wu X, Ji X, Zhang Q, Lin Y, Chen W . A novel canine model of portal vein stenosis plus thioacetamide administration-induced cirrhotic portal hypertension with hypersplenism. Cell Biochem Biophys. 2011; 62(1):245-55. DOI: 10.1007/s12013-011-9272-7. View

He X, Huang T, Wang P, Peng X, Li W, Wang J . Morphological and biomechanical remodeling of the hepatic portal vein in a swine model of portal hypertension. Ann Vasc Surg. 2011; 26(2):259-67. DOI: 10.1016/j.avsg.2011.10.007. View

Huang H, Chang C, Wang S, Lee F, Teng T, Lee J . The roles of angiotensin II receptors in the portosystemic collaterals of portal hypertensive and cirrhotic rats. J Vasc Res. 2012; 49(2):160-8. DOI: 10.1159/000332347. View

Kanda T, Yoshikawa T, Ohno Y, Kanata N, Koyama H, Takenaka D . CT hepatic perfusion measurement: comparison of three analytic methods. Eur J Radiol. 2011; 81(9):2075-9. DOI: 10.1016/j.ejrad.2011.07.003. View

Katada Y, Shukuya T, Kawashima M, Nozaki M, Imai H, Natori T . A comparative study between arterial spin labeling and CT perfusion methods on hepatic portal venous flow. Jpn J Radiol. 2012; 30(10):863-9. DOI: 10.1007/s11604-012-0127-y. View

Berzigotti A, Seijo S, Reverter E, Bosch J . Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013; 7(2):141-55. DOI: 10.1586/egh.12.83. View

Ma G, Bai R, Jiang H, Hao X, Ling Z, Li K . Assessment of hemodynamics in a rat model of liver cirrhosis with precancerous lesions using multislice spiral CT perfusion imaging. Biomed Res Int. 2013; 2013:813174. PMC: 3705863. DOI: 10.1155/2013/813174. View

10.

Oberholzer H, Bester M, Van Der Schoor C . Rats on a high-energy diet showing no weight gain present with ultrastructural changes associated with liver fibrosis. Ultrastruct Pathol. 2013; 37(4):267-72. DOI: 10.3109/01913123.2013.790527. View

11.

Bosch J, Garcia-Pagan J . Complications of cirrhosis. I. Portal hypertension. J Hepatol. 2000; 32(1 Suppl):141-56. DOI: 10.1016/s0168-8278(00)80422-5. View

12.

Weber L, Boll M, Stampfl A . Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003; 33(2):105-36. DOI: 10.1080/713611034. View

13.

Tsai M, Iwakiri Y, Cadelina G, Sessa W, Groszmann R . Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology. 2003; 125(5):1452-61. DOI: 10.1016/j.gastro.2003.07.014. View

14.

Kojima H, Tanigawa N, Komemushi A, Kariya S, Sawada S . Computed tomography perfusion of the liver: assessment of pure portal blood flow studied with CT perfusion during superior mesenteric arterial portography. Acta Radiol. 2004; 45(7):709-15. DOI: 10.1080/02841850410001385. View

15.

Hernandez-Guerra M, Garcia-Pagan J, Bosch J . Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol. 2005; 39(4 Suppl 2):S131-7. DOI: 10.1097/01.mcg.0000155513.17715.f7. View

16.

Treiber G, Csepregi A, Malfertheiner P . The pathophysiology of portal hypertension. Dig Dis. 2005; 23(1):6-10. DOI: 10.1159/000084720. View

17.

Guan S, Zhao W, Zhou K, Peng W, Mao J, Tang F . CT perfusion at early stage of hepatic diffuse disease. World J Gastroenterol. 2005; 11(22):3465-7. PMC: 4316005. DOI: 10.3748/wjg.v11.i22.3465. View

18.

Katsuta Y, Zhang X, Ohsuga M, Akimoto T, Komeichi H, Shimizu S . Hemodynamic features of advanced cirrhosis due to chronic bile duct ligation. J Nippon Med Sch. 2005; 72(4):217-25. DOI: 10.1272/jnms.72.217. View

19.

Iwakiri Y, Groszmann R . The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006; 43(2 Suppl 1):S121-31. DOI: 10.1002/hep.20993. View

20.

Su Z, Shan H, Ke W, He B, Zheng R . Portalsystemic hemodynamic changes in chronic severe hepatitis B: An ultrasonographic study. World J Gastroenterol. 2008; 14(5):795-9. PMC: 2684011. DOI: 10.3748/wjg.14.795. View